|

MK-5684 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ODM-208

Pipeline

Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1

Indications

  • Castration-Resistant Prostatic Cancer1
  • Metastasis1
  • Cancer1

San Francisco, California1 trial

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

UCSF Medical Center at Mission Bay ( Site 0034)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.